- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-198/19 P: Judgment of the Court (First Chamber) of 27 June 2024 – Teva UK Ltd, Teva Pharmaceuticals Europe BV, Teva Pharmaceutical Industries Ltd v European Commission, European Generic medicines Association AISBL (EGA) (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Agreements, decisions and concerted practices – Potential competition – Restriction of competition by object – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement)
ECLI:EU:UNKNOWN:62019CA0198
62019CA0198
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2024/4827
12.8.2024
(Case C-198/19 P)
(Appeal - Competition - Pharmaceutical products - Market for perindopril - Article 101 TFEU - Agreements, decisions and concerted practices - Potential competition - Restriction of competition by object - Strategy to delay the market entry of generic versions of perindopril - Patent dispute settlement agreement)
(C/2024/4827)
Language of the case: English
Parties
Appellants: Teva UK Ltd, Teva Pharmaceuticals Europe BV, Teva Pharmaceutical Industries Ltd (represented by: A. Richard and D. Tayar, avocats)
Other parties to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, and by G. Peretz KC, and subsequently by F. Castilla Contreras and C. Vollrath, acting as Agents, and by G. Peretz KC), European Generic medicines Association AISBL (EGA)
Intervener in support of the other party: United Kingdom of Great Britain and Northern Ireland (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent)
Operative part of the judgment
The Court:
1.Dismisses the appeal;
2.Orders Teva UK Ltd, Teva Pharmaceuticals Europe BV and Teva Pharmaceutical Industries Ltd to bear their own costs and to pay those incurred by the European Commission;
3.Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.
—
(1)
OJ C 164, 13.5.2019.
ELI: http://data.europa.eu/eli/C/2024/4827/oj
ISSN 1977-091X (electronic edition)
—
* * *
Language of the case: English.